Navigation Links
AMT Presents Positive Results of Phase I/II Study with Lead Product,at Annual Meeting of American Society of Gene Therapy

e). The study was started in August 2005 and finalized in April 2007, and in effect demonstrates the safety and efficacy of AMT-010. All patients are now taking part in a follow-up trial, which will last for 12 months.

Efficacy

The primary endpoints of the study were either median fasting plasma triglyceride (TG) levels after administration of AMT-010 equal to or less than 10 mmol/L, or a 40% reduction in median fasting plasma TG after administration on top of a fat-free diet. For all subjects a substantial reduction of median TG levels was observed. Three patients (one from the low dose and 2 from the mid dose group) hit the primary endpoint, with TG levels below the target level of 10 mmol/L or a 40% reduction in TG levels. In two patients of the mid dose group the reduction of TG coincided with expression of active LPL in the injected muscle at 26-32 weeks after vector administration, which clearly demonstrates long-term expression of the therapeutic gene.

Safety

Furthermore, the study shows that AMT-010 was well-tolerated; there were no drug-related severe adverse events, and no dose-limiting toxicity. There was no measurable sign of local or systemic inflammation and no increase in creatinine phosphokinase concentrations, which implies that the impact on tissue function is limited and not harmful to humans.

About AMT

Amsterdam Molecular Therapeutics BV (AMT) is a gene therapy company founded by scientists of the University of Amsterdam Medical Center (AMC) in 1998. AMT focuses on the development of gene-based therapies for orphan diseases. AMT's technology allows long-term gene expression and the specific delivery of therapeutic genes to target organs or tissues. AMT has optimized and validated the production of AAV-based gene therapy vectors. The result is a unique, stable, and scalable GMP production platform. Its lead product, AMT-011, is in pre-registration trials for the first indication: treatment of comp
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:7/22/2014)... PharmaTech (Cayman) Inc. (NYSE: WX ), a leading ... in China and the ... financial results for the second quarter of 2014 after the ... (which will be Thursday morning, August 14, 2014 Shanghai time). ... section of the Company,s website at http://www.wuxiapptec.com . ...
(Date:7/22/2014)... SOUTH EASTON, Mass. , July 22, ... ("PBI" or the "Company") and Parabase Genomics ... have entered into a strategic research and ... of the collaboration, PBI will develop a ... neonatal molecular diagnostics and newborn confirmatory testing ...
(Date:7/22/2014)... , July 22, 2014 ... umfassenden Schutz von Pharmazeuten und Krankenpflegern ... Equashield ( http://www.equashield.com ), ... System Transfer Devices, CSTDs) für gefährliche Medikamente, ernannte ... und Hersteller von medizinischen Produkten, zu seinem ...
Breaking Medicine Technology:WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 3Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 4Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2
... Cheyenne Regional Medical Center is expanding its ... an AirLife Denver medical helicopter service in ... Regional and HCA-HealthONE, which operates AIRLIFE Denver. ... blue and sonic green helicopter will be stationed in ...
... Systems, Inc. (Nasdaq: DCTH ) announced today that ... Lazard Capital Markets, Eighth Annual Healthcare Conference on Tuesday, November ...  Mr. Hobbs will provide an overview of the Company,s business ... this conference is by invitation only.  Delcath will offer a ...
Cached Medicine Technology:Cheyenne Regional Medical Center Announces New Air Ambulance Service Partnership with HealthONE's AirLife Denver 2Cheyenne Regional Medical Center Announces New Air Ambulance Service Partnership with HealthONE's AirLife Denver 3Delcath to Present at the Lazard Healthcare Conference on November 15 2Delcath to Present at the Lazard Healthcare Conference on November 15 3
(Date:7/22/2014)... American Society of Hematology (ASH) will honor Michael DeBaun, ... Robert P. Hebbel, MD, of the University of Minnesota ... Prize for their significant research advances in the area ... named for the late Ernest Beutler, MD, a past ... years, is a two-part lectureship that recognizes major translational ...
(Date:7/22/2014)... Society of Hematology (ASH) will present the Society,s highest ... Achievement in Hematology, to Kanti R. Rai, MD, of ... Medicine for his 50-year career combining landmark clinical leukemia ... patient care. , The Wallace H. Coulter Award ... individual who has been a vital contributor to the ...
(Date:7/22/2014)... New guidelines on cholesterol treatment and cardiovascular risk assessment ... of dying from atherosclerotic cardiovascular disease or of having ... a similar risk profile (based on age, smoking history, ... this finding for when and how aggressively to treat ... Journal of Men,s Health , a peer-reviewed publication from ...
(Date:7/22/2014)... Los Angeles, CA (PRWEB) July 22, 2014 ... leads the way in providing resources, educational tools and ... that tell the stories of prevention, treatment and recovery. ... drama BLACK BOX will spotlight some of these resources ... Mental Health Services Administration helpline and treatment website at ...
(Date:7/22/2014)... 2014 (HealthDay News) --,High school lacrosse players are facing ... as games, a new study finds. Although the ... 22 percent are concussions, researchers report. They note a ... lead to better ways to protect student athletes. ... underscores the need to learn more about these injuries," ...
Breaking Medicine News(10 mins):Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 2Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 4Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 3Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 4Health News:ABC’s BLACK BOX Spotlights Mental Health and Available Resources in Upcoming Episode 2Health News:Injuries on the Increase in High School Lacrosse, Study Shows 2Health News:Injuries on the Increase in High School Lacrosse, Study Shows 3
... Del., Jan. 8 DuPont (NYSE: DD ... Protection,Agency for Agility(TM) SG herbicide, a new product ... for broad spectrum weed control, including,ALS resistant species. ... of action in a single formulation to offer,convenient, ...
... spending slowed for first time since its inception in ... new Medicare prescription drug plan was largely responsible for ... which was double the increase in spending from the ... Medicare spending reached $401.3 billion, an increase from $338 ...
... found that Medicare spending across the country varies greatly. But ... the same no matter which region a person lives in. ... is no value to the excess costs in high-spending areas. ... as a model suggests this is not correct. While ...
... promoting innovation and fuelled by the brain gain of ... biotech industry only needs a more favourable investment climate ... of therapies and medicines both new and low-cost ... Long considered a skillful product replicator, China today boasts ...
... announced today,that it has entered into an agreement with ... product. Breckenridge expects to file an,ANDA with the FDA ... AG will,supply and Breckenridge will market and distribute the ... agreement, Breckenridge will submit an ANDA to the,U.S. Food ...
... a colonoscopy can play a life-saving role by encouraging ... cancer screenings, according to new research from the University ... provide important information to combat myths and fears that ... their doctors often fail to address. In a randomized ...
Cached Medicine News:Health News:New DuPont(TM) Agility(TM) SG Herbicide Offers Wheat Growers Answers to Changing Weed Control Needs 2Health News:Medicare Drug Plan Fuels Health-Care Spending 2Health News:Medicare Drug Plan Fuels Health-Care Spending 3Health News:Higher Medicare spending yields mixed bag for patients 2Health News:Higher Medicare spending yields mixed bag for patients 3Health News:China's biotech industry: An Asian dragon is growing 2Health News:China's biotech industry: An Asian dragon is growing 3Health News:China's biotech industry: An Asian dragon is growing 4Health News:China's biotech industry: An Asian dragon is growing 5Health News:China's biotech industry: An Asian dragon is growing 6Health News:China's biotech industry: An Asian dragon is growing 7Health News:Breckenridge Pharmaceutical Signs Long Term Agreement with Helm AG (Hamburg, Germany) 2Health News:Colonoscopy fears overcome when patients support patients 2Health News:Colonoscopy fears overcome when patients support patients 3
Easy to use , Allow for a flexible washing , Uniform and efficient , Very robust and reliable , Adjustable to all well shapes , Rack included (not autoclavable) , Autoclavable at 121C , No e...
... with a 25-microplate capacity ... and aspiration and dispense ... On-board software for user ... programs. External vacuum pump ...
... microplate washers available to handle ... cell-based assays. Embla 384 Cell ... have been optimized to avoid ... robotic compatible and have been ...
ELISA Microplate Washer, Manual...
Medicine Products: